Severe autoimmune hemolytic anemia following receipt of SARS‐CoV‐2 mRNA vaccine
| Autor: | Patricia A. R. Brunker, Pavan K. Bendapudi, Janet Lo, Rebecca Karp Leaf, Hanny Al-Samkari, David E. Leaf, Sanjay R V Gadi, Rebecca R. Saff, David B. Sykes |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
biology
business.industry SARS‐CoV‐2 mRNA vaccine Immunology Autoantibody Case Report Hematology Case Reports direct antiglobulin test medicine.disease Mycophenolic acid Immunoglobulin G Immune system medicine biology.protein Immunology and Allergy Rituximab Antibody Autoimmune hemolytic anemia business Packed red blood cells autoimmune hemolytic anemia medicine.drug |
| Zdroj: | Transfusion |
| ISSN: | 1537-2995 0041-1132 |
| Popis: | Large clinical trials have demonstrated the overall safety of vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, reports have emerged of autoimmune phenomena, including vaccine-associated myocarditis,1 immune thrombocytopenia,2 and immune thrombotic thrombocytopenia.3 4 Here we present a novel case of a young woman who developed life-threatening autoimmune hemolytic anemia (AIHA) after her first dose of a SARS-CoV-2 mRNA vaccine. Notably, initial direct antiglobulin testing was negative using standard anti-IgG reagents, which are "blind" to certain immunoglobulin (IgG) isotypes. Further testing using an antiglobulin reagent that detects all IgG isotypes was strongly positive and confirmed the diagnosis of AIHA. The patient required transfusion with 13 units of packed red blood cells, as well as treatment with corticosteroids, rituximab, mycophenolate mofetil, and immune globulin. As efforts to administer SARS-CoV-2 vaccines continue globally, clinicians must be aware of potential autoimmune sequelae of these therapies. This article is protected by copyright. All rights reserved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text